Kidney Week 2017: Call for Abstracts

ASN will accept abstract submissions electronically from April 12, 2017 through June 8, 2017 (2:00 p.m. EDT). ASN requires ASN User Logins and completed financial and other relationship DISCLOSURES FOR ALL AUTHORS. Please allow adequate time to gather this information. (The call for late-breaking clinical trials will open in July.)

Table of Contents

New for 2017

New or updated abstract categories!

  • 002 AKI: Repair and Regeneration
  • 003 AKI: Clinical and Translational
  • 305 CKD: Clinical Trials and Tubulointerstitial Disorders
  • 308 Mechanisms of Tubulointerstitial Fibrosis
  • 503 Diabetes Mellitus and Obesity: Translational
  • 610 Dialysis: Infection
  • 1101 Hypertension: Basic and Experimental: Neural and Inflammatory Mechanisms
  • 1102 Hypertension: Basic and Experimental: Renal Causes and Consequences
  • 1104 Hypertension: Clinical and Translational: Salt and Hypertension
  • 1105 Hypertension: Clinical and Translational: Genetics and Epigenetics
  • 1106 Hypertension: Clinical and Translational: Secondary Causes

General Guidelines

Your abstract submission must meet the following criteria for ASN consideration:

  • ASN will accept an abstract submission if the abstract (research article):
    • has not been submitted for publication or has not been accepted for presentation (oral or poster) at another meeting, or
    • has been submitted for publication but not yet accepted for publication by June 8, 2017.
  • ASN will not accept an abstract submission if the abstract (research article):
    • has already been published,
    • has been accepted for publication, or
    • will have already been presented (oral or poster) at another meeting or press conference by the date of the ASN meeting.
  • The lead author (i.e., individual submitting the abstract and presenting the abstract if accepted) has the authority to submit the abstract and transfer copyright on behalf of the co-authors and company sponsors.
  • All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.

Submission Information

  1. All abstracts must be submitted electronically through the ASN abstract submission site by Thursday, June 8, 2017, 2:00 p.m. EDT for consideration.
  2. Lead Author: A lead author must be assigned for each abstract submission.
    • This individual is the first author listed in the submission and has the primary responsibility for communications with ASN.
    • This individual must have an ASN User Login with current contact information for submission.
    • Click here if the lead author has an ASN User Login but forgot his/her password.
    • Click here if the lead author needs to create an ASN User Login.
    • This individual must have a current financial and other relationship disclosure affidavit on file with ASN. (Click here for the ASN Conflict of Interest and Disclosure Policy.)
    • This individual is responsible for ensuring that all co-authors and company sponsors approve the submission, publication, and potential presentation.
    • This individual will give the oral or poster presentation if the submission is accepted. The lead author should feel comfortable presenting and answering questions in English.
  3. Co-Authors: Each co-author must have an ASN User Login with current contact information and must have a current financial and other relationship disclosure affidavit on file with ASN. The co-authors will be listed in the order provided during submission.
    • Click here if the co-author has an ASN User Login but forgot his/her password.
    • Click here if the co-author needs to create an ASN User Login.
  4. Authors and Contributors: With regard to authorship credit, ASN has adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the current update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: "Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3."

    Note the full text of the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals. In addition, with regard to contributors, ASN has adopted the following statement of editorial policy from the Information for Authors of the Annals of Internal Medicine: "Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts (Daskalopoulou, Jacobs). These writers should be acknowledged on the byline or in the Acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The editors consider failure to acknowledge these contributors ghostwriting, which is contrary to Annals' editorial policy."
  5. An abstract submission may contain a maximum of 2,500 characters, and the count includes characters and spaces in the following: Authors/Institutions, Title, Body, Figure, and Table.
  6. The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. If the lead author does not receive an email confirmation within two business days of submission, please email ts.acsupport@thomson.com immediately. Lack of email confirmation indicates that ASN did not receive the submission.
  7. There is no limit to the number of abstracts that an individual may submit. However, there is a $65 nonrefundable processing fee per submission. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
  8. Upon abstract submission, the lead author and co-authors agree to all copyright transfer terms and the ASN embargo policy.
  9. Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers.
  10. Changes: It is important that the lead author checks the abstract data carefully before submission. For submitted abstracts needing minimal changes through June 13, 2017, the lead author can email education@asn-online.org with the abstract number in the subject line and the lead author's name in the message body. After June 13, no changes will be allowed, including author updates. If accepted for presentation/publication, your abstract will be printed as it was submitted with any changes as of June 13.
  11. Withdrawals: The lead author can request abstract withdrawal through June 30, 2017 by emailing education@asn-online.org. Please note the abstract number in the email subject line and the lead author's name in the email body. The $65 processing fee is nonrefundable. After June 30, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.

Assignment, Notification & Presentation

All abstract submissions are peer reviewed and authors' names and institutions are blinded to reviewers. ASN will email notifications to the lead authors of all abstract submissions by August 11, 2017. Accepted abstracts will be assigned to one of the following:

  • "High-Impact Clinical Studies" Oral Session: This session for clinical abstracts will be held on Saturday, November 4, 10:30 a.m. – 12:30 p.m. Each abstract presentation will be followed by audience questions, facilitated by the session moderator(s). Abstracts accepted for the high profile sessions will be included in the ASN's 2017 Abstract Supplement of JASN on November 4.
  • Oral Abstract Sessions: Oral Abstract Sessions will be held on Thursday, November 2, Friday, November 3, and Saturday, November 4 at 4:30 p.m. – 6:30 p.m. Each abstract presentation is allotted eight minutes followed by an additional four minutes of audience questions, facilitated by the session moderator(s). Abstracts accepted for oral presentations will be included in the ASN's 2017 Abstract Supplement of JASN, which will be posted online by October 13.
  • Poster Presentations: Poster presentations will be available for viewing on Thursday, November 2, Friday, November 3, and Saturday, November 4 at 9:30 a.m. – 4:30 p.m. in the exhibit hall. If accepted for poster presentation, the lead author or a co-author must be available at the poster board from 10:00 a.m. to 12:00 p.m. for presentation and discussion. Abstracts accepted for poster presentations will be included in the ASN's 2017 Abstract Supplement of JASN, which will be posted online by October 13.
  • Publication Only: Some abstracts will be included in the ASN's 2017 Abstract Supplement of JASN but not presented during Kidney Week. To request removal from the Abstract Supplement, the lead author must check the box during the submission process that states "Please do not include my abstract in the ASN's 2017 Abstract Supplement of the Journal of the American Society of Nephrology if my abstract is not selected for an oral or poster presentation." The Abstract Supplement will be posted online by October 13.

It is the responsibility of the lead authors to share the notifications with their co-authors. If you are a lead author and have not received your notification by August 11, 2017, please email ts.acsupport@thomson.com and note the abstract number in the email subject line and the lead author's name in the email body.

The presenting authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and make their own housing reservations. Please note that early registration closes on August 30, 2017.

Confidential Advanced Access

All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.